Tadalafil entfaltet seine Wirkung über eine selektive Hemmung der PDE5, wodurch die Konzentration von cGMP im glatten Muskelgewebe stabil bleibt. Diese biochemische Modulation resultiert in einer langanhaltenden Relaxation der Gefäßwände. Der Wirkstoff wird nach oraler Einnahme effizient resorbiert, mit einer Bioverfügbarkeit von rund 80 %. Seine Halbwertszeit von bis zu 36 Stunden ist innerhalb dieser Substanzklasse außergewöhnlich. Abgebaut wird er in der Leber, hauptsächlich durch CYP3A4, mit anschließender biliärer Exkretion. Typische unerwünschte Wirkungen entstehen durch eine verstärkte Vasodilatation, etwa Kopfschmerzen oder Flush. Pharmakologisch wird cialis generika vor allem durch die verlängerte Wirkungsdauer charakterisiert.
Multimodality treatment of allergic rhinitis
Allergic rhinitis affects approximately 50 million
people in the U.S., and the prevalence is rising.
Allergies represent the 2nd leading cause of
chronic disease in the U.S., costing the
healthcare system $18 billion annually.
3.4 million days lost from work annually and 2
The head and neck region is the “shock organ”
Sneezing – 84% Anterior rhinorrhea – 76% Itchy eyes – 71%
Nasal congestion – 70% Itchy nose – 56%
Sinus pressure – 52% Headache – 49% Watery eyes – 49%
Sneezing Rhinorrhea Congestion Symptoms
Competitive H1 binding Lipophilic (crosses the BBB)
Anticholinergic effect (urinary retention, xerostomia)
Diphenhydramine, chlorpheniramine, hydroxyzine
Non-competitive H1 binding Lipophobic (less sedation, improved performance)
Terfenadine, fexofenadine, loratadine (des), azelastine,
Cardiac effects (macrolides, systemic antifungals)
Itchiness, airway smooth muscle contraction
Binds to alpha-1 and alpha-2 receptors
Displaced norepinephrine from receptors
Cetirizine = fexofenadine > loratadine
Effects on the task of driving: diphen.>EtOH>fex=placebo
Response time: EtOH>diphen>fex=placebo
Testing scores in children (10-12): non-atopic>loratadine>diphen
Levels peak - 2 hours (½ life 3-4 hours)
Local potency greater than with systemic
Risks – rhinitis medicamentosa (>7 days)
May produce urinary retention or insomnia
Phenylephrine (Neo-synephrine®) Oxymetazoline (Afrin, Dristan®)
Use with caution in patients with a history
of: HTN, CAD, glaucoma, hyperthyroidism,
Naphazoline (Privine®) Epinephrine (Primatene®)
MAO inhibitor use, urinary retention, CVA
Pseudoephendrine is only available choice
Binds to intracellular receptors (mRNA,
Prevents initiation of the allergic cascade
Major side effects include HA, nosebleeds
Decreased recruitment and migration of
Posterior subcapsular cataracts not proven
Use when congestion is a major symptom
Chronic use leads to growth suppression in
Decreased activity of basophils and mast cells
Decreased migration of APC, T-cells, B-cells
Initially identified in the 1930’s – called
Combination with antihistamine has been
Effects of cysteinyl leukotrienes (C4,D4,E4)
Low side effect profile - Isolated cases of
liver toxicity and Churg-Strauss syndrome
LTE4 attracts neutro, eos in asthmatic patients
Useful in nasal polyposis +/- ASA triad?
Topical ipratropium bromide (Atrovent®)
Useful before anticipated antigen exposure
Cromolyn sodium (Nasalcrom®, Intal®)
Begin with AM loading dose, repeat in 6
Use with caution in elderly patients,
Late phase inhibition of eos and neutrophils
Try a non-sedating AH ± decongestant or a leukotriene
Consider intranasal steroid alone or combined
Inadequate response to initial therapy
Significant impact on the quality of life Co-morbidities are occurring
Combined therapy ± oral corticosteroids, antibiotics
In general, the lowest effective dose of a
You must be aware of side effects, safety
Medication strategies must be tailored to
You may have to follow a moving target!
IVINS, PHILLIPS & BARKER H. STEWART DUNN, JR. CHARTERED JAMES S.Y. IVINS (1885-1960) CARROLL J. SAVAGE PERCY W. PHILLIPS (1892-1969) ERIC R. FOX 1700 PENNSYLVANIA AVENUE, N.W., SUITE 600 RICHARD B. BARKER (1906-1988) LESLIE JAY SCHNEIDER WASHINGTON, D.C. 20006-4723 ROBERT H. WELLEN OF COUNSEL KEVIN P. O'BRIEN TELEPHONE (202) 393-7600 JAY W.
ESTATUTO DE LA FEDERACIÓN DEPORTIVA PERUANA DE BASKETBALL Estatuto: Regla que tiene fuerza de Ley. Fines, Funciones y Obligaciones de la Federación Admisión, Renuncia y Exclusión de los Asociados Visto el Informe Nº 267-GENADAF-2000 de 07 de Noviembre 2000; Que las Federaciones Deportivas Nacionales son los órganos rectores de su correspondiente disciplina deportiva debiendo r